Any current/future new fundraising through debt or equity?

The company plans to fund the new Abu Dhabi facility through a mix of internal accruals and debt. They will be approaching bankers both in India and Abu Dhabi for funding the expansion. No explicit mention of new equity fundraising in the provided excerpts. For other expansions (e.g., consumer electronics business), capex plans are being worked on but no specific fundraising details provided yet. Existing and upcoming contracts are backed by take-or-pay agreements ensuring firm commitments, reducing funding risk.

Any current/future capex/capital investment/strategic investment?

Expansion in India: Adding 25 million pen capacity with two new lines, one under qualification (arrived Dec), the second arriving end April/beginning May, targeting total capacity of 80 million pens by FY '28. UAE (Abu Dhabi) Facility: 18-20 months lead time for setup; funding through mix of internal accruals, debt, and support from Abu Dhabi bankers. Around 50-60% capacity commitments secured. Facility will provide business continuity and cater to large volume contracts; potential further expansion if 50 million additional pens commitment arises. Consumer Electronics Business: Capex plans f

Future growth expectations in sales/revenue/volumes?

Healthcare segment revenue grew 158% Y-o-Y for 9 months FY '26, indicating high growth potential. Consumer segment revenue declined slightly (-1%) but expected to rebound as global economies improve and trade agreements finalize. Current pen volume guidance for FY '26 is ~30 million, with expected gradual scale-up; UAE expansion planned to support higher volumes by FY '28. Innovator contracts could add 50-100 million pen volumes over the next few years, but timelines uncertain (launch 2-3 years post agreement). UK subsidiary has 7 new projects in pipeline, expected to deliver strong growth ove

Future growth expectations in earnings/operating earnings/profits/EPS?

Strong revenue growth driven by healthcare segment: 158% growth YoY in 9 months FY '26; consumer segment stable with slight decline. Expansion in pen injector capacity from 30 million to 80 million pens by FY '28, supporting volume growth. Innovator contracts expected to add significant volumes (50-100 million pens), but likely post-2028. New consumer electronics segment targeted for high-complexity, high-margin parts; scalable long-term growth opportunity. EBITDA margins improved by 720 bps YoY to 29% in 9 months FY '26; PAT margins increased by 590 bps to 17.2%. Price erosion anticipated to

Current/ Expected Orderbook/ Pending Orders?

The capacity expansion in India (totaling around 80 million pens) is more or less fully backed by commercial contracts. The Abu Dhabi expansion capacity is around 50% to 60% secured through capacity commitments. The company anticipates being fully backed by contracts for Abu Dhabi facility approximately 18 months out. For the innovator business, a potential of 50 to 100 million pens is seen, but exact timelines (2029-2031) are uncertain. Take-or-pay contracts are in place, ensuring minimum volume commitments from customers. The company has ongoing advanced stage discussions, with potential new

IN US

Sale is live|00:00:00left today

Shaily Engineering Plastics LtdQ4 FY27Consumer Durables

Shaily Engineering Plastics Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,850P/E: 89.5Market Cap: ₹12.7K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Healthcare segment revenue grew 158% Y-o-Y for 9 months FY '26, indicating high growth potential.
→Consumer segment revenue declined slightly (-1%) but expected to rebound as global economies improve and trade agreements finalize.
→Current pen volume guidance for FY '26 is ~30 million, with expected gradual scale-up; UAE expansion planned to support higher volumes by FY '28.
→Innovator contracts could add 50-100 million pen volumes over the next few years, but timelines uncertain (launch 2-3 years post agreement).
→UK subsidiary has 7 new projects in pipeline, expected to deliver strong growth over 3-4 years.
→Consumer electronics segment expected to scale over next 12-18 months with high-margin, complex parts.
→Capacity utilization projected around 70-80% by FY '28 with UAE expansion.
→Overall, long-term growth driven by healthcare (GLP-1 drugs), innovator partnerships, and expanding international markets.

Margin guidance

Category 3

→Strong revenue growth driven by healthcare segment: 158% growth YoY in 9 months FY '26; consumer segment stable with slight decline.
→Expansion in pen injector capacity from 30 million to 80 million pens by FY '28, supporting volume growth.
→Innovator contracts expected to add significant volumes (50-100 million pens), but likely post-2028.
→New consumer electronics segment targeted for high-complexity, high-margin parts; scalable long-term growth opportunity.
→EBITDA margins improved by 720 bps YoY to 29% in 9 months FY '26; PAT margins increased by 590 bps to 17.2%.
→Price erosion anticipated to stabilize after initial 24 months despite competitive pressures.
→UAE expansion planned by end FY '28 to support large-volume contracts and diversify operations.
→Overall, management remains bullish on strong earnings growth with improving margins and capacity-driven scale-up over next 2-3 years.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company plans to fund the new Abu Dhabi facility through a mix of internal accruals and debt.
→They will be approaching bankers both in India and Abu Dhabi for funding the expansion.
→No explicit mention of new equity fundraising in the provided excerpts.
→For other expansions (e.g., consumer electronics business), capex plans are being worked on but no specific fundraising details provided yet.
→Existing and upcoming contracts are backed by take-or-pay agreements ensuring firm commitments, reducing funding risk.

Order book

Yes

→The capacity expansion in India (totaling around 80 million pens) is more or less fully backed by commercial contracts.
→The Abu Dhabi expansion capacity is around 50% to 60% secured through capacity commitments.
→The company anticipates being fully backed by contracts for Abu Dhabi facility approximately 18 months out.
→For the innovator business, a potential of 50 to 100 million pens is seen, but exact timelines (2029-2031) are uncertain.
→Take-or-pay contracts are in place, ensuring minimum volume commitments from customers.
→The company has ongoing advanced stage discussions, with potential new contracts for innovative GLP-1 molecules possibly signing in the current year.
→GLP-1 injector supplies have already started for launches in Canada, Brazil, India, Middle East, and Turkey.
→Overall, the order book is solid and supports ongoing and upcoming capacity expansions.

Capex plans

Yes

→Expansion in India: Adding 25 million pen capacity with two new lines, one under qualification (arrived Dec), the second arriving end April/beginning May, targeting total capacity of 80 million pens by FY '28.
→UAE (Abu Dhabi) Facility: 18-20 months lead time for setup; funding through mix of internal accruals, debt, and support from Abu Dhabi bankers. Around 50-60% capacity commitments secured. Facility will provide business continuity and cater to large volume contracts; potential further expansion if 50 million additional pens commitment arises.
→Consumer Electronics Business: Capex plans for this new segment are being worked on, with no concrete details yet.
→Overall expansions are largely backed by commercial contracts and take-or-pay agreements to mitigate risks.

How does Shaily Engineering Plastics Ltd rank vs peers in Consumer Durables?

Pro feature

1Shaily Engineering Plastics Ltd

Rev 2Mar 3

See full Consumer Durables sector rankings

Want more stocks like Shaily Engineering Plastics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio